Who are lisaftoclax +BTK inhibitor's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lisaftoclax-btk-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

lisaftoclax +BTK inhibitor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

lisaftoclax +BTK inhibitor (lisaftoclax +BTK inhibitor) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BCL-2 inhibitor + BTK inhibitor combination. Area: Oncology.

phase 3 BCL-2 inhibitor + BTK inhibitor combination BCL-2 and BTK (Bruton's tyrosine kinase) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

lisaftoclax +BTK inhibitor (lisaftoclax +BTK inhibitor) — Ascentage Pharma Group Inc.. Lisaftoclax is a BCL-2 inhibitor combined with a BTK inhibitor to promote apoptosis in cancer cells while blocking B-cell survival signaling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
lisaftoclax +BTK inhibitor TARGET	lisaftoclax +BTK inhibitor	Ascentage Pharma Group Inc.	phase 3	BCL-2 inhibitor + BTK inhibitor combination	BCL-2 and BTK (Bruton's tyrosine kinase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BCL-2 inhibitor + BTK inhibitor combination class)

Ascentage Pharma Group Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lisaftoclax +BTK inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/lisaftoclax-btk-inhibitor. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab